A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 390
Last updated 2026-05-01
Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Conditions
- Focal Epilepsy
Interventions
- DRUG
-
BHV-7000
BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
- DRUG
-
BHV-7000
BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
- DRUG
-
Matching placebo taken once daily
- DRUG
-
BHV-7000
BHV-7000 75 mg. Participants willtake blinded investigational product(IP) once daily
- DRUG
-
Matching placebo taken once daily
Sponsors & Collaborators
-
Biohaven Therapeutics Ltd.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-14
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Austria
- Belgium
- Chile
- Croatia
- Czechia
- France
- Hungary
- Netherlands
- Poland
- Slovenia
- South Africa
- Switzerland
Study Locations
More Related Trials
-
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
NCT05493293 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
NCT01501383 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT06315322 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
NCT02687711 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
NCT03083665 ·Status: COMPLETED ·Phase: PHASE3
-
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
NCT00699283 ·Status: TERMINATED ·Phase: PHASE3
-
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
NCT06377930 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
NCT03283371 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT02625090 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
NCT03373383 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
NCT00740623 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT02495844 ·Status: COMPLETED ·Phase: PHASE2
-
Human Epilepsy Project 2: Resistant Focal Seizures Study
NCT03531008 ·Status: COMPLETED
-
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
NCT01339559 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
NCT01167335 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
NCT03739840 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of GWP42006 in People With Focal Seizures - Part B
NCT02365610 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
NCT01364597 ·Status: COMPLETED ·Phase: PHASE3
-
A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093
NCT02171234 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of GWP42006 in People With Focal Seizures - Part A
NCT02369471 ·Status: COMPLETED ·Phase: PHASE2
-
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
NCT00698581 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT05109234 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT00228969 ·Status: COMPLETED ·Phase: PHASE2